			Home About us Contact

Heparin Concentrations (heparin + concentration)

Distribution by Scientific Domains

Medical Sciences	66%

Selected Abstracts

Heparin concentrations in neonates during cardiopulmonary bypass as measured by the activated clotting time and anti-Xa assay

ANAESTHESIA, Issue 12 2009
J. Keogh
No abstract is available for this article. [source]

Amperometric Sensor for Heparin: Sensing Mechanism and Application in Human Blood Plasma Analysis

ELECTROANALYSIS, Issue 13-14 2006
Jan Langmaier
Abstract Voltammetric measurements of heparin at a rotating glassy carbon (GC) electrode coated with a polyvinylchloride membrane are reported. A spin-coating technique is used to prepare thin membranes (20,40,,m) with a composition of 25% (w/w) PVC, 1,1,-dimethylferrocene as a reference electron donor for the GC|membrane interface, nitrophenyl octyl ether (o -NPOE) or bis(2-ethylhexyl) sebacate (DOS) as a plasticizer, and hexadecyltrimethylammonium tetrakis(4-chlorophenyl) borate (HTMATPBCl) or tridodecylmethylammonium tetrakis(4-chlorophenyl) borate (TDMATPBCl) as a background electrolyte. It is shown that the electrodes coated with either the HTMA+/o -NPOE (DOS) or TDMA+/o -NPOE (DOS) membrane provide a comparable amperometric response towards heparin (1,10,U mL,1) in the aqueous solution of 0.1,M LiCl. However, only the membranes formulated with TDMATPBCl can be used for an amperometric assay of heparin in human blood plasma with a detection limit of 0.2,U mL,1. Effects of membrane composition, heparin concentration, rotation speed and sweep rate on the voltammetric behavior of heparin provide some insight into the sensing mechanism. Theoretical analysis of the amperometric response is outlined, and the numeric simulation of the voltammetric behavior is presented. [source]

Quantification of heparin-induced TFPI release: a maximum release at low heparin dose

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, Issue 6 2002
Michiel J. B. Kemme
Aims Heparin releases tissue factor pathway inhibitor (TFPI) from the endothelium and this release may decrease after repeated high dose heparin administration. The primary aim was to investigate and quantify this phenomenon during a short low dose heparin infusion. Also, the effects of heparin on tissue plasminogen activator (t-PA) were studied. Methods Nine healthy, nonsmoking, male volunteers (range 19,23 years) received a continuous heparin infusion (2000 IU) over 40 min. The endothelial TFPI release rate was estimated from the total TFPI concentration profile using a pharmacokinetic model. Results , Mean ,±,s.d. ,total ,and ,free ,TFPI ,increased ,from ,62.9 ± 9.4/8.3 ± 2.1 ng ml,1 at baseline to 237.2 ± 40.9/111.0 ± 19.9 ng ml,1 after 40 min infusion. The relationship between heparin concentration (anti-IIa activity) and TFPI concentration followed a maximum effect model and a clockwise loop (proteresis) was observed. The TFPI release rate rapidly increased to maximum of 200 ± 45 µg min,1 after 17.5 min heparin infusion but did not increase further although heparin concentrations further doubled. In contrast to TFPI, t-PA antigen decreased from 5.6 ± 1.0 at baseline to 4.5 ± 1.0 ng ml,1 at the end of infusion (t = 40 min) (difference of 1.1 ng ml,1 (95% confidence interval; 0.9, 1.3). Conclusions Our application of concentration-effect models and pharmacokinetic principles to these haemostatic variables showed that endothelial TFPI release has a maximum that is already reached at low heparin dose, corresponding with an anti-IIa activity of 0.08 IU ml,1. The relationship between anti-IIa activity and TFPI release rate showed signs of acute tolerance (clockwise loop) indicating exhaustion of endothelial TFPI pools. These findings may be of importance for the heparin dose used in conditions such as unstable angina, in which the favourable effects of heparin have been ascribed to its ability to release TFPI. [source]

Heparin modulates the growth and adherence and augments the growth-inhibitory action of TNF-, on cultured human keratinocytes

JOURNAL OF CELLULAR BIOCHEMISTRY, Issue 2 2004
Ilkka T. Harvima
Abstract Previous works suggest the involvement of mast cells in the epithelialization of chronic wounds. Since heparin is a major mediator stored in the secretory granules of mast cells, the purpose of this work was to elucidate the function of heparin in epithelialization using in vitro culture models. For this, low- and high-calcium media in monolayer and epithelium cultures of keratinocytes were used. Also, an assay based on keratinocyte adherence onto plastic surface was used as well. Heparin (0.02,200 ,g/ml) inhibited keratinocyte growth in a non-cytotoxic and dose-dependent manner in low- and high-calcium media, Keratinocyte-SFM® and DMEM, in the absence of growth factors and serum. Also, heparin inhibited the growth of keratinocyte epithelium in the presence of 10% fetal calf serum and DMEM. Instead, in the presence of Keratinocyte-SFM and growth factors, heparin at 2 ,g/ml inhibited the growth by 18% but at higher heparin concentrations the inhibition was reversed to baseline. TNF-, is another preformed mediator in mast cell granules and it inhibited keratinocyte growth in monolayer and epithelium cultures. Interestingly, heparin at 2,20 ,g/ml augmented or even potentiated this growth-inhibitory effect of TNF-,. The association of TNF-, with heparin was shown by demonstrating that TNF-, bound tightly to heparin-Sepharose chromatographic material. However, heparin could not augment TNF-,-induced cell cycle arrest at G0/G1 phase or intercellular adhesion molecule-1 expression in keratinocytes. In the cell adherence assay, heparin at 2 ,g/ml inhibited significantly by 12,13% or 33% the adherence of keratinocytes onto the plastic surface coated with fibronectin or collagen, respectively, but this inhibition was reversed back to baseline at 20 or 200 ,g/ml heparin. Also, heparin affected the cell membrane rather than the protein coat on the plastic surface. In conclusion, heparin not only inhibits or modulates keratinocyte growth and adherence but it also binds and potentiates the growth-inhibitory function of TNF-,. © 2004 Wiley-Liss, Inc. [source]

Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Issue 8 2004
R. Al Dieri
Summary., Heparin can be quantified with antifactor Xa and IIa tests (aXa, aIIa) but the anticoagulant power of heparin depends upon plasma properties as well as upon heparin concentrations and thus differs between subjects. Measuring the effect, as with the activated partial thromboplastin time (APTT) therefore is clinically more relevant. Here we investigate the use of the endogenous thrombin potential (ETP) for this purpose. In 12 volunteers 9000 IU of four heparins of different mol. wt distributions were injected. Samples were taken at 11 time points between 0 and 24 h. With the exception of the 0 and 24-h time points, heparin could be demonstrated by its aIIa and aXa activity in virtually all samples. The APTT showed the effect of this heparin in 34% of the samples; the ETP in 80%. This is partly due to the wide margins of the normal values, caused by large interindividual variation [coefficient of variation (CV) approximately 12% for the APTT, approximately 17% for the ETP]. The intraindividual variation is much smaller (CV approximately 4% for the APTT, approximately 5% for the ETP). Relative to the baseline value of the individual, the heparin effect was recognized by the APTT in 55% of the cases and by the ETP in 98%. There were no large differences between the different types of heparin. [source]